Is adding Bactrim (trimethoprim/sulfamethoxazole) to Fortum (ceftazidime) effective in the eradication phase of melioidosis treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Adding Bactrim to Ceftazidime in Melioidosis Eradication Phase

Do not add Bactrim (TMP-SMX) to ceftazidime during the intensive phase of melioidosis treatment, as combination therapy provides no mortality benefit over ceftazidime monotherapy. 1

Intensive Phase Treatment Strategy

The treatment of melioidosis follows a two-phase approach: an intensive phase followed by an eradication phase. Understanding this distinction is critical to answering your question correctly.

Intensive Phase (First 14+ Days)

  • Use ceftazidime monotherapy (100 mg/kg/day) OR a carbapenem (meropenem/imipenem preferred) for at least 14 days as the intensive phase treatment. 2, 3

  • Adding TMP-SMX to ceftazidime during the intensive phase does not reduce mortality. Two large randomized controlled trials (n=449 patients) demonstrated identical in-hospital mortality rates: 25.1% with ceftazidime alone versus 26.6% with ceftazidime plus TMP-SMX (OR 1.08,95% CI 0.7-1.7, p=0.73). 1

  • This finding contradicts an older 1992 trial 4 that suggested benefit from combination therapy, but the more recent and methodologically superior 2005 meta-analysis 1 should guide practice.

  • Carbapenems (meropenem or imipenem) demonstrate superior outcomes compared to ceftazidime in severe melioidosis and are now preferred first-line agents. 3

  • Extend the intensive phase to 4-8 weeks or longer for patients with critical illness, extensive pulmonary disease, deep-seated abscesses, osteomyelitis, septic arthritis, or neurologic involvement. 2, 3

Eradication Phase (After Intensive Phase)

This is where TMP-SMX becomes essential—but as monotherapy, not in combination with ceftazidime:

  • TMP-SMX is the drug of choice for the 3-6 month eradication phase to prevent the 13% relapse rate seen over 10 years. 2, 3

  • Use weight-based dosing: <40 kg: 160/800 mg (1 DS tablet) twice daily; 40-60 kg: 240/1200 mg (1.5 DS tablets) twice daily; >60 kg: 320/1600 mg (2 DS tablets) twice daily. 3

  • Add folic acid 0.1 mg/kg up to 5 mg daily to prevent antifolate effects without compromising antimicrobial activity. 3

  • TMP-SMX monotherapy for 20 weeks is as effective as TMP-SMX plus doxycycline combination therapy in preventing recurrence. 3

Alternative Regimens When TMP-SMX Cannot Be Used

  • Amoxicillin-clavulanate (20/5 mg/kg every 8 hours, maximum 1500/375 mg every 8 hours) is the preferred alternative for pregnant women, children, or patients with TMP-SMX intolerance, though it is significantly less effective than TMP-SMX. 3, 5

  • Doxycycline can be used as an alternative if TMP-SMX is contraindicated. 2

Critical Pitfalls to Avoid

  • Do not use ertapenem, azithromycin, or moxifloxacin—B. pseudomallei is inherently resistant to these agents. 3, 5

  • Avoid ceftriaxone and cefotaxime, as these are associated with higher mortality rates compared to ceftazidime. 3

  • Do not continue ceftazidime into the eradication phase—switch to oral TMP-SMX after completing the intensive phase. 2, 3

Special Considerations for CNS Involvement

  • For central nervous system melioidosis, use higher TMP-SMX dosing at 8/40 mg/kg IV/PO every 12 hours (up to 320/1600 mg) and extend duration to 4-8 weeks or longer. 3

References

Research

Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005

Guideline

Dosing of Trimethoprim-Sulfamethoxazole for Melioidosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Suspected Melioidosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Melioidosis Treatment and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.